Subscribe To

Price Alert Latest News Economic Calendar News

RYZB / RayzeBio stock opens with a big gain, to push valuation up to $1.4 billion

Investors cheered RayBio Inc. as it debuted on Wall Street, as the California-based radiopharmaceutical company's stock RYZB, +39.13% opened 38.9% above the initial public offering price. The company had raised $311 million as it sold 17.3 million shares in the IPO, up from an expected 14.4 million shares, with the IPO pricing at $18 a share, at the top of the expected range. Read More

Demo Live Account See Partner Details

Content Topics

Rayzebio

Stock

Opens

With

Gain

Push

Valuation

Billion

RYZB

Posted: Sep 15 2023, 11:48

Author Name: Market Watch

RYZB News

By Seeking Alpha
October 10, 2023

RayzeBio: Initiating Coverage With Buy Rating And A Price Target Of $43

Initiating RayzeBio, Inc. coverage with a Buy rating and common stock price target of $43 based on my risk-adjusted NPV discounted cash flow model, re

By Market Watch
September 15, 2023

RayzeBio stock opens with a big gain, to push valuation up to $1.4 billion

Investors cheered RayBio Inc. as it debuted on Wall Street, as the California-based radiopharmaceutical company's stock RYZB, +39.13% opened 38.9% abo

By Proactive Investors
September 15, 2023

RayzeBio to go public at $1B market valuation

RayzeBio Inc shares are expected to begin trading on the Nasdaq after Friday's open as the radiopharmaceutical company's upsized initial public offeri

By Market Watch
September 15, 2023

RayzeBio valued at nearly $1 billion as upsized IPO prices at top of expected range

RayzeBio Inc. RYZB, has secured a near-$1 billion market valuation, as the California-based radiopharmaceutical company's upsized initial public offer

By Market Watch
September 11, 2023

RayzeBio sets IPO terms, to be valued at up to $1 billion

RayzeBio Inc. RYZB, has set terms for its initial public offering, as the California-based radiopharmaceutical company with a tumor treatment in a Pha

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.